| Dr Matthew Dedmon, MD | |
|
101 Manning Dr, Chapel Hill, NC 27599 | |
| (919) 966-8596 | |
| Not Available |
| Full Name | Dr Matthew Dedmon |
|---|---|
| Gender | Male |
| Speciality | Otolaryngology |
| Experience | 13 Years |
| Location | 101 Manning Dr, Chapel Hill, North Carolina |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1184910614 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207YX0901X | Otolaryngology - Otology & Neurotology | 2018-00496 (North Carolina) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| University Of North Carolina Hospital | Chapel hill, NC | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Unc Physicians And Associates | 0648181156 | 1656 |
News Archive
Scientists at the Helmholtz Zentrum München (HMGU) working in cooperation with the Ludwig-Maximilians-Universität Hospital (KUM) and the Technischen Universität München (TUM) tested for the first time X-ray dark-field radiography on a living organism for the diagnosis of lung disease.
Emergent BioSolutions Inc. announced today that its Investigational New Drug (IND) application, to commence a Phase I clinical trial for its anthrax monoclonal antibody therapeutic, has cleared U.S. Food and Drug Administration (FDA) review. The Phase I study will evaluate the safety and pharmacokinetics of the company's fully human monoclonal antibody being developed as a parenteral post-exposure therapy for individuals who have symptoms of anthrax disease. In pre-clinical therapeutic studies, Emergent's monoclonal antibody was found to be effective.
The Barbara Ann Karmanos Cancer Institute announced today it received a $3 million grant from the Herrick Foundation. The initial gift of $1 million launches The Herrick Foundation Cancer Research Challenge, a special initiative to increase research funding at the Karmanos Cancer Institute over the next four years. The additional commitment of $2 million will be given in match funding.
British scientists have developed a tabletop DNA test laboratory that can cut the diagnosis of disease and infection from hours to 30 minutes. This new test laboratory will soon begin trials in UK hospitals.
Early exposure to nicotine can trigger widespread genetic changes that affect formation of connections between brain cells long after birth, a new Yale-led study has found. The finding helps explains why maternal smoking has been linked to behavioral changes such as attention deficit and hyperactivity disorder, addiction and conduct disorder.
› Verified 1 days ago
| Entity Name | University Of North Carolina At Chapel Hill |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1780669200 PECOS PAC ID: 0648181156 Enrollment ID: O20031105000359 |
News Archive
Scientists at the Helmholtz Zentrum München (HMGU) working in cooperation with the Ludwig-Maximilians-Universität Hospital (KUM) and the Technischen Universität München (TUM) tested for the first time X-ray dark-field radiography on a living organism for the diagnosis of lung disease.
Emergent BioSolutions Inc. announced today that its Investigational New Drug (IND) application, to commence a Phase I clinical trial for its anthrax monoclonal antibody therapeutic, has cleared U.S. Food and Drug Administration (FDA) review. The Phase I study will evaluate the safety and pharmacokinetics of the company's fully human monoclonal antibody being developed as a parenteral post-exposure therapy for individuals who have symptoms of anthrax disease. In pre-clinical therapeutic studies, Emergent's monoclonal antibody was found to be effective.
The Barbara Ann Karmanos Cancer Institute announced today it received a $3 million grant from the Herrick Foundation. The initial gift of $1 million launches The Herrick Foundation Cancer Research Challenge, a special initiative to increase research funding at the Karmanos Cancer Institute over the next four years. The additional commitment of $2 million will be given in match funding.
British scientists have developed a tabletop DNA test laboratory that can cut the diagnosis of disease and infection from hours to 30 minutes. This new test laboratory will soon begin trials in UK hospitals.
Early exposure to nicotine can trigger widespread genetic changes that affect formation of connections between brain cells long after birth, a new Yale-led study has found. The finding helps explains why maternal smoking has been linked to behavioral changes such as attention deficit and hyperactivity disorder, addiction and conduct disorder.
› Verified 1 days ago
| Entity Name | Chatham Hospital Inc |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1093712655 PECOS PAC ID: 5991604902 Enrollment ID: O20061104000243 |
News Archive
Scientists at the Helmholtz Zentrum München (HMGU) working in cooperation with the Ludwig-Maximilians-Universität Hospital (KUM) and the Technischen Universität München (TUM) tested for the first time X-ray dark-field radiography on a living organism for the diagnosis of lung disease.
Emergent BioSolutions Inc. announced today that its Investigational New Drug (IND) application, to commence a Phase I clinical trial for its anthrax monoclonal antibody therapeutic, has cleared U.S. Food and Drug Administration (FDA) review. The Phase I study will evaluate the safety and pharmacokinetics of the company's fully human monoclonal antibody being developed as a parenteral post-exposure therapy for individuals who have symptoms of anthrax disease. In pre-clinical therapeutic studies, Emergent's monoclonal antibody was found to be effective.
The Barbara Ann Karmanos Cancer Institute announced today it received a $3 million grant from the Herrick Foundation. The initial gift of $1 million launches The Herrick Foundation Cancer Research Challenge, a special initiative to increase research funding at the Karmanos Cancer Institute over the next four years. The additional commitment of $2 million will be given in match funding.
British scientists have developed a tabletop DNA test laboratory that can cut the diagnosis of disease and infection from hours to 30 minutes. This new test laboratory will soon begin trials in UK hospitals.
Early exposure to nicotine can trigger widespread genetic changes that affect formation of connections between brain cells long after birth, a new Yale-led study has found. The finding helps explains why maternal smoking has been linked to behavioral changes such as attention deficit and hyperactivity disorder, addiction and conduct disorder.
› Verified 1 days ago
| Entity Name | Chatham Hospital Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1689967457 PECOS PAC ID: 4284807868 Enrollment ID: O20111026000545 |
News Archive
Scientists at the Helmholtz Zentrum München (HMGU) working in cooperation with the Ludwig-Maximilians-Universität Hospital (KUM) and the Technischen Universität München (TUM) tested for the first time X-ray dark-field radiography on a living organism for the diagnosis of lung disease.
Emergent BioSolutions Inc. announced today that its Investigational New Drug (IND) application, to commence a Phase I clinical trial for its anthrax monoclonal antibody therapeutic, has cleared U.S. Food and Drug Administration (FDA) review. The Phase I study will evaluate the safety and pharmacokinetics of the company's fully human monoclonal antibody being developed as a parenteral post-exposure therapy for individuals who have symptoms of anthrax disease. In pre-clinical therapeutic studies, Emergent's monoclonal antibody was found to be effective.
The Barbara Ann Karmanos Cancer Institute announced today it received a $3 million grant from the Herrick Foundation. The initial gift of $1 million launches The Herrick Foundation Cancer Research Challenge, a special initiative to increase research funding at the Karmanos Cancer Institute over the next four years. The additional commitment of $2 million will be given in match funding.
British scientists have developed a tabletop DNA test laboratory that can cut the diagnosis of disease and infection from hours to 30 minutes. This new test laboratory will soon begin trials in UK hospitals.
Early exposure to nicotine can trigger widespread genetic changes that affect formation of connections between brain cells long after birth, a new Yale-led study has found. The finding helps explains why maternal smoking has been linked to behavioral changes such as attention deficit and hyperactivity disorder, addiction and conduct disorder.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Matthew Dedmon, MD 101 Manning Dr, Chapel Hill, NC 27514-4220 Ph: () - | Dr Matthew Dedmon, MD 101 Manning Dr, Chapel Hill, NC 27599 Ph: (919) 966-8596 |
News Archive
Scientists at the Helmholtz Zentrum München (HMGU) working in cooperation with the Ludwig-Maximilians-Universität Hospital (KUM) and the Technischen Universität München (TUM) tested for the first time X-ray dark-field radiography on a living organism for the diagnosis of lung disease.
Emergent BioSolutions Inc. announced today that its Investigational New Drug (IND) application, to commence a Phase I clinical trial for its anthrax monoclonal antibody therapeutic, has cleared U.S. Food and Drug Administration (FDA) review. The Phase I study will evaluate the safety and pharmacokinetics of the company's fully human monoclonal antibody being developed as a parenteral post-exposure therapy for individuals who have symptoms of anthrax disease. In pre-clinical therapeutic studies, Emergent's monoclonal antibody was found to be effective.
The Barbara Ann Karmanos Cancer Institute announced today it received a $3 million grant from the Herrick Foundation. The initial gift of $1 million launches The Herrick Foundation Cancer Research Challenge, a special initiative to increase research funding at the Karmanos Cancer Institute over the next four years. The additional commitment of $2 million will be given in match funding.
British scientists have developed a tabletop DNA test laboratory that can cut the diagnosis of disease and infection from hours to 30 minutes. This new test laboratory will soon begin trials in UK hospitals.
Early exposure to nicotine can trigger widespread genetic changes that affect formation of connections between brain cells long after birth, a new Yale-led study has found. The finding helps explains why maternal smoking has been linked to behavioral changes such as attention deficit and hyperactivity disorder, addiction and conduct disorder.
› Verified 1 days ago
Dr. William W Shockley, MD Otolaryngology Medicare: Medicare Enrolled Practice Location: 101 Manning Dr, Chapel Hill, NC 27599 Phone: 919-966-8596 Fax: 919-843-5515 | |
Charles Ebert Jr., M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 101 Manning Dr, Rm 1107g W Wing, Chapel Hill, NC 27514 Phone: 919-966-4131 | |
Julian Andrew Vellucci, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 101 Manning Dr, Chapel Hill, NC 27514 Phone: 984-974-1000 | |
Peter George Chikes, M.D. Otolaryngology Medicare: Not Enrolled in Medicare Practice Location: 170 Manning Dr, Physicians Office Building, Cb 7070, Chapel Hill, NC 27599 Phone: 919-966-3342 | |
Dr. Jeffrey Martin Blumberg, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 101 Manning Dr, Chapel Hill, NC 27514 Phone: 984-974-6484 | |
Carlton Zdanski, Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 101 Manning Dr, Chapel Hill, NC 27514 Phone: 919-843-4810 |